Auro Laboratories Ltd
AUROLABAuro Laboratories Ltd
AUROLAB
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 28.29 | 4.16 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.92 | 6.65 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Auro Laboratories Limited is engaged in the business of bulk drugs. It manufactures active pharmaceutical ingredients (APIs), intermediates and generic formulations.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 28.33 | 36.00 | 41.30 | 47.78 | 44.76 | 55.01 | 51.96 | 53.83 | 55.14 | 40.19 | ||||||||||
Raw Materials | 16.38 | 20.08 | 24.66 | 30.39 | 23.99 | 27.64 | 33.76 | 37.30 | 29.04 | 30.33 | ||||||||||
| Power & Fuel Cost | 1.02 | 1.29 | 1.48 | 1.64 | 1.69 | 1.60 | 1.67 | 2.08 | 2.43 | |||||||||||
| Employee Cost | 2.37 | 2.72 | 2.80 | 2.87 | 3.48 | 3.64 | 3.70 | 3.76 | 3.91 | |||||||||||
| Selling & Administrative Expenses | 2.58 | 2.52 | 3.27 | 4.18 | 5.03 | 5.84 | 5.86 | 4.73 | 7.31 | |||||||||||
| Operating & Other expenses | 2.76 | 4.44 | 2.23 | 0.75 | 3.33 | 4.29 | 1.25 | 0.63 | 0.28 | |||||||||||
EBITDA | 3.22 | 4.95 | 6.86 | 7.95 | 7.24 | 12.00 | 5.72 | 5.33 | 12.17 | 9.86 | ||||||||||
| Depreciation/Amortization | 0.68 | 0.86 | 0.93 | 1.01 | 1.02 | 1.04 | 1.02 | 1.07 | 1.09 | 1.09 | ||||||||||
| PBIT | 2.54 | 4.09 | 5.93 | 6.94 | 6.22 | 10.96 | 4.70 | 4.26 | 11.08 | 8.77 | ||||||||||
| Interest & Other Items | 1.66 | 1.18 | 1.21 | 0.87 | 0.58 | 0.46 | 0.83 | 0.81 | 0.74 | 0.65 | ||||||||||
| PBT | 0.88 | 2.91 | 4.72 | 6.07 | 5.64 | 10.50 | 3.87 | 3.45 | 10.34 | 8.12 | ||||||||||
| Taxes & Other Items | 0.00 | 2.11 | 1.19 | 1.67 | 1.58 | 3.32 | 1.03 | 1.00 | 2.55 | 1.95 | ||||||||||
| Net Income | 0.88 | 0.80 | 3.53 | 4.40 | 4.06 | 7.18 | 2.84 | 2.45 | 7.79 | 6.17 | ||||||||||
| EPS | 1.41 | 1.28 | 5.66 | 7.06 | 6.51 | 11.52 | 4.56 | 3.93 | 12.50 | 9.90 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Auro Laboratories Ltd | 22.41 | 4.16 | — |
| Sun Pharmaceutical Industries Ltd | 45.12 | 6.44 | 0.75% |
| Cipla Ltd | 28.85 | 4.44 | 0.88% |
| Torrent Pharmaceuticals Ltd | 69.10 | 16.69 | 0.83% |
Price Comparison
Compare AUROLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
AUROLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Auro Laboratories declined 81.73% to Rs 0.36 crore in the quarter ended September 2024 as against Rs 1.97 crore during the previous quarter ended September 2023. Sales declined 76.88% to Rs 3.10 crore in the quarter ended September 2024 as against Rs 13.41 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3.1013.41 -77 OPM %23.2322.60 - PBDT0.753.00 -75 PBT0.482.73 -82 NP0.361.97 -82 Powered by Capital Market - Live
Auro Laboratories will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live
Net profit of Auro Laboratories rose 5.63% to Rs 0.75 crore in the quarter ended June 2024 as against Rs 0.71 crore during the previous quarter ended June 2023. Sales declined 43.81% to Rs 5.72 crore in the quarter ended June 2024 as against Rs 10.18 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales5.7210.18 -44 OPM %23.0811.39 - PBDT1.271.25 2 PBT1.000.98 2 NP0.750.71 6 Powered by Capital Market - Live
Auro Laboratories will hold a meeting of the Board of Directors of the Company on 9 August 2024Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 2.91%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.02% to 0.01%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 12.1%, vs industry avg of 15.27%